M. Morin

发表

Pharmacological rescue of mutant p53 conformation and function.

B. Foster, H. Coffey, M. Morin, 1999, Science.

Biochemical effects and therapeutic potential of tunicamycin in murine L1210 leukemia.

M. Morin, R. Bernacki, M. J. Morin, 1983, Cancer research.

DNA vaccines.

R. Webster, D. Montefiori, N. Letvin, 1996, AIDS research and human retroviruses.

A pathway for entry of retroviruses into the host through M cells of the respiratory tract

M. Morin, B. Fields, M. Morin, 1994, The Journal of experimental medicine.

The biochemical and ultrastructural effects of tunicamycin and D‐glucosamine in L1210 leukemic cells

M. Morin, C. Porter, R. Bernacki, 1983, Journal of cellular physiology.

Helical CT and renal calculi.

M. Morin, M. J. Morin, 2000, AJR. American journal of roentgenology.

Serotype-dependent induction of pulmonary neutrophilia and inflammatory cytokine gene expression by reovirus

J. Paulauskis, M. Morin, L. Kobzik, 1996, Journal of virology.

Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein

Antonio Polley, M. Morin, M. Robinson, 2021, bioRxiv.

Increased cell surface EGF receptor expression during the butyrate-induced differentiation of human HCT-116 colon tumor cell clones.

M. Morin, D. Nathan, S. Burkhart, 1990, Experimental cell research.

IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2

M. Diamond, Antonio Polley, M. Morin, 2022, Science Immunology.

Preclinical Efficacy of IMM-BCP-01, a Highly Active Patient-Derived Anti-SARS-CoV-2 Antibody Cocktail

M. Diamond, Antonio Polley, M. Morin, 2021, bioRxiv.

Human multidrug resistant KB cells overexpress protein kinase C: involvement in drug resistance.

M. Morin, E. McKeegan, T. Tritton, 1989, Cancer communications.

Reovirus infection in rat lungs as a model to study the pathogenesis of viral pneumonia

M. Morin, B. Fields, A. Warner, 1996, Journal of virology.

Normal and Neoplastic Hematopoiesis

M. Morin, M. J. Morin, 1984, The Yale Journal of Biology and Medicine.

Effects of a membrane sugar analogue, 6-deoxy-6-fluoro-D-galactose, on the L1210 leukemic cell ectosialyltransferase system.

M. Morin, C. Porter, C. R. Petrie, 1983, Biochemical pharmacology.

Membrane Recycling. Ciba Foundation Symposium 92

M. Morin, 1983, The Yale Journal of Biology and Medicine.

Potentiation of butyrate-induced differentiation in human colon tumor cells by deoxycholate.

M. Morin, D. Nathan, T. Desai, 1993, Cancer letters.

DNA immunization for influenza virus: studies using hemagglutinin- and nucleoprotein-expressing DNAs.

R. Webster, M. Morin, D. Feltquate, 1997, The Journal of infectious diseases.

Role of different lymphoid tissues in the initiation and maintenance of DNA-raised antibody responses to the influenza virus H1 glycoprotein

R. Webster, M. Morin, H. Robinson, 1996, Journal of virology.

Mechanisms involved in the induction of malignant cell differentiation.

M. Reiss, A. Sartorelli, M. Morin, 1986, Advances in enzyme regulation.

Inhibition of glycoprotein biosynthesis by the inducers of HL-60 cell differentiation, aclacinomycin A and marcellomycin.

A. Sartorelli, M. Morin, M. J. Morin, 1984, Cancer research.

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

L. Pustilnik, P. Miller, B. Boman, 1997, Cancer research.

Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.

L. Pustilnik, M. Morin, T. Smolarek, 1999, The Journal of pharmacology and experimental therapeutics.

From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents

Michael J Morin, M. Morin, M. J. Morin, 2000, Oncogene.

Function of the anthracycline amino group in cellular transport and cytotoxicity.

A. Sartorelli, M. Morin, T. Burke, 1987, Molecular pharmacology.

Dissociation of protein kinase C activation from phorbol ester-induced maturation of HL-60 leukemia cells.

M. Morin, D. Kreutter, A. Caldwell, 1985, The Journal of biological chemistry.

Microsomal activation and increased production of 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide (m-AMSA)-dependent, topoisomerase-associated DNA lesions in nuclei from human HL-60 leukemia cells.

L. Gorsky, M. Morin, M. J. Morin, 1990, Biochemical pharmacology.

Rapid increase in the activity of DNA topoisomerase I, but not topoisomerase II, in HL-60 promyelocytic leukemia cells treated with a phorbol diester.

L. Gorsky, M. Morin, S. M. Cross, 1989, Cancer communications.

Disparate effects of activators of protein kinase C on HL-60 promyelocytic leukemia cell differentiation.

H. Rasmussen, A. Sartorelli, M. Morin, 1987, The Journal of biological chemistry.

Antibody-forming cell response to virus challenge in mice immunized with DNA encoding the influenza virus hemagglutinin

R. Webster, M. Morin, H. Robinson, 1995, Journal of virology.

Halogenated L-fucose and D-galactose analogues: synthesis and metabolic effects.

M. Morin, J. Sufrin, R. Bernacki, 1980, Journal of medicinal chemistry.

HALOGENATED L-FUCOSE AND D-GALACTOSE ANALOGS: SYNTHESIS AND METABOLIC EFFECTS

M. Morin, J. Sufrin, R. Bernacki, 1980 .

IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation

M. Morin, J. P. Finn, M. Robinson, 2023, mAbs.